Cargando…

Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19

Detalles Bibliográficos
Autores principales:	Perricone, Carlo, Bartoloni, Elena, Gerli, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2020
Materias:	Editorial Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667946/ https://www.ncbi.nlm.nih.gov/pubmed/33227067 http://dx.doi.org/10.5114/reum.2020.100088

Ejemplares similares

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
por: Perricone, Carlo, et al.
Publicado: (2020)

Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial
por: Perricone, Carlo, et al.
Publicado: (2023)

COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
por: Perricone, Carlo, et al.
Publicado: (2020)

Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future
por: Bursi, Roberto, et al.
Publicado: (2021)

Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections
por: Perricone, Carlo, et al.
Publicado: (2021)

Polyangiitis overlap syndrome: a rare clinical entity
por: Bruno, Lorenza, et al.
Publicado: (2023)

The potential role of 'non-rheumatic’ therapies in rheumatic disease
por: Massarotti, Elena M, et al.
Publicado: (2013)

Colchicine as a Potential Treatment Choice for COVID-19 Patients in Developing Countries: COVID-19 and Colchicine
por: Ghang, Byeongzu, et al.
Publicado: (2022)

Design, synthesis, and biological evaluation of biotinylated colchicine derivatives as potential antitumor agents
por: Wang, Chao, et al.
Publicado: (2021)

COVID-19 – rheumatic diseases and rheumatologists
por: Maślińska, Maria
Publicado: (2021)

Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?
por: Bartoloni, Elena, et al.
Publicado: (2018)

Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
por: Bianconi, Vanessa, et al.
Publicado: (2023)

Unattended compared to traditional blood pressure measurement in patients with rheumatoid arthritis: a randomised cross-over study
por: Bartoloni, Elena, et al.
Publicado: (2021)

Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review
por: Papadopoulos, Christodoulos, et al.
Publicado: (2020)

Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment
por: Cafaro, Giacomo, et al.
Publicado: (2022)

COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments
por: Ouédraogo, Dieu-Donné, et al.
Publicado: (2020)

Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases
por: Suresh, Lakshmanan
Publicado: (2021)

Is There a Role for Colchicine in Acute Coronary Syndromes?
por: Nidorf, Stefan M, et al.
Publicado: (2015)

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases
por: Schulze-Koops, Hendrik
Publicado: (2017)

Treatment with biologics during pregnancy in patients with rheumatic diseases
por: Förger, Frauke
Publicado: (2017)

Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents
por: Costagliola, Giorgio, et al.
Publicado: (2021)

Effect of an antimitotic agent colchicine on thioacetamide hepatotoxicity.
por: Mangipudy, R S, et al.
Publicado: (1996)

COVID-19, colchicine and glycemia
por: Ilias, Ioannis, et al.
Publicado: (2021)

Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel
por: Bombuwala, Karunananda, et al.
Publicado: (2006)

Vaccinations in rheumatic diseases
por: Szwejkowska, Martyna, et al.
Publicado: (2020)

Colchicine treatment in COVID-19: the remaining unsolved question
por: Rojas-Villarraga, Adriana, et al.
Publicado: (2021)

Photolysis and cytotoxicity of the potentially toxic composition of daylily flower: colchicine
por: Zhang, Lin, et al.
Publicado: (2023)

Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions
por: Blanch-Rubió, Josep, et al.
Publicado: (2020)

Peripheral Nervous System Involvement in Sjögren’s Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren’s Syndrome
por: Cafaro, Giacomo, et al.
Publicado: (2021)

THE MECHANISM OF COLCHICINE INHIBITION OF MITOSIS : I. Kinetics of Inhibition and the Binding of H(3)-Colchicine
por: Taylor, Edwin W.
Publicado: (1965)

The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study
por: Salehzadeh, Farhad, et al.
Publicado: (2022)

Comorbidities and multimorbidity in rheumatic diseases
por: Filipowicz-Sosnowska, Anna
Publicado: (2019)

Cardiovascular Involvement in Sjögren’s Syndrome
por: Atzeni, Fabiola, et al.
Publicado: (2022)

Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022)

COVID-19 in patients with gout on colchicine
por: Pelechas, Eleftherios, et al.
Publicado: (2021)

The Impact of SARS-CoV-2 Outbreak on Primary Sjögren's Syndrome: An Italian Experience
por: Carubbi, Francesco, et al.
Publicado: (2020)

Natural Compounds as Antimicrobial Agents
por: Franco, Carlos Manuel, et al.
Publicado: (2020)

Preliminary results of clinical use of colchicine in COVID-19 treatment
por: Knack, Rafael Silvestre, et al.
Publicado: (2021)

Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases
por: Richez, Christophe, et al.
Publicado: (2020)

Vaccinations in autoimmune inflammatory rheumatic diseases
por: Szenborn, Leszek
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3eq4qnnc632724mrnflt5fassm